sameAs
Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerizationVascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activationReceptor tyrosine kinase-mediated angiogenesisStructural determinants of growth factor binding and specificity by VEGF receptor 2Structural determinants of vascular endothelial growth factor-D receptor binding and specificityStructural and mechanistic insights into VEGF receptor 3 ligand binding and activationVascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veinsVascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.Hyperplasia of lymphatic vessels in VEGF-C transgenic miceClaudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel developmentVEGF guides angiogenic sprouting utilizing endothelial tip cell filopodiaA truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development.Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis.Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1Genesis and pathogenesis of lymphatic vessels.Genomic organization of human and mouse genes for vascular endothelial growth factor C.Functional Importance of a Proteoglycan Coreceptor in Pathologic LymphangiogenesisOverexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy.Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle.Functional interaction of VEGF-C and VEGF-D with neuropilin receptors.Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis.Lymphatic Vessels in Regenerative Medicine and Tissue Engineering.The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands.Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis.Factors regulating the substrate specificity of cytosolic phospholipase A2-alpha in vitro.Substrate efflux propensity is the key determinant of Ca2+-independent phospholipase A-β (iPLAβ)-mediated glycerophospholipid hydrolysisVascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium.Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation.Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain.The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function.Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity.Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts.Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis.
P50
Q24311715-F9A63640-B6F2-4D01-AFC9-0471FB4863FEQ24321792-83DA93F6-0D1B-44D1-80FE-9597F58DC4B3Q24337821-31BAA5B0-2B58-4250-8DA0-9A6AF0F3070EQ27001612-628250B6-3D14-461B-9918-05366A84870EQ27659686-AF6E406D-E2B1-4391-B423-4AA5159800A8Q27666332-29E42E2B-EE95-4CAD-AB10-B9761B0D97AFQ27679183-C72C89E7-9CDF-4B9B-AD60-31EF7C551968Q28186603-0E4093E2-B18E-4081-A957-789151A8315EQ28200101-6A32BCF1-D056-4CFA-A625-6A398285B0B4Q28238886-9C4F6406-5F1C-4AC2-8308-BAFCE6E09F21Q28586394-C702B5F7-4794-49F4-876E-42D38F24DADDQ29617501-3C7919A6-C11D-4B5D-AC6E-856BC97A1AC2Q30537569-CB5D25AE-81ED-40B8-B078-A0243AACA34CQ33234980-C54531C9-A1AA-489A-8992-7EC43DEB4EECQ33731734-78DE23F9-82CD-4BF3-820B-8EC2D6A6619EQ33760923-884C77E0-4A9D-478E-926C-BAA646270A98Q33884989-62C7CB7B-13C3-4167-89DA-0C653DE215F1Q35207200-AF36D443-7922-4D51-804D-77C2F0AC9894Q36884488-34419F2E-7414-4EF7-B4DD-2D69010C1F5DQ37079690-DD9A67BE-5DBF-4A45-9DFC-E1E8C7FB815AQ37388790-3924E21F-3AC7-4D3A-AD29-818BABB8DC98Q37419632-AD4CD1F8-7685-4150-A8DD-671B04CC4AB6Q38311836-145F0B03-877E-40D3-AF42-518C169D7792Q38329140-DD32C7E4-0C12-44B1-B02F-960BDFF2E355Q38824712-109E1727-832B-426E-A407-8579008C152EQ39131192-8DD0E795-64E4-4619-B5F4-B4E96E565494Q39203228-EB40CE8C-9D0E-45A0-955E-C94E752EFF06Q39633000-ABACFA76-2656-46B5-BC8A-A86B3FCFD344Q39715315-D0482C69-15E6-466D-A1BE-2E107B427790Q40414498-D0CF7F24-1BEE-4DD8-A02A-894A966909CCQ40721888-CE4B9D31-5439-4278-A11A-5EBF3576F635Q42572244-2BF2F744-54E7-4F5C-8300-33E8A83E0E85Q42862047-F7636100-E52F-46F1-A43D-633E3FEE18CCQ46222501-4F95EE9B-01B6-49AE-A5B7-2A46EE90D72EQ46535751-3E3B7298-E090-4831-9220-02870E9BBF42Q47405553-641779C8-07A4-4667-835A-599068B49A87Q48009173-14E8ECF2-A5A7-4BBE-973A-8D2A9CFA30A0Q51012326-DE4B879B-A2FA-44D1-8D68-CC6C93CE0E6DQ54227029-79201F7C-8E8B-4F55-AE4C-56340DCE8885Q54485417-DD91FA70-0BF5-4EBD-826E-630BBF200396
P50
description
biochemist
@en
bithcheimiceoir
@ga
finnischer Chemiker
@de
químicu finlandés
@ast
name
Michael Jeltsch
@ast
Michael Jeltsch
@ca
Michael Jeltsch
@de
Michael Jeltsch
@en
Michael Jeltsch
@es
Michael Jeltsch
@fr
Michael Jeltsch
@ga
Michael Jeltsch
@nl
Michael Jeltsch
@sl
Michael Jeltsch
@sq
type
label
Michael Jeltsch
@ast
Michael Jeltsch
@ca
Michael Jeltsch
@de
Michael Jeltsch
@en
Michael Jeltsch
@es
Michael Jeltsch
@fr
Michael Jeltsch
@ga
Michael Jeltsch
@nl
Michael Jeltsch
@sl
Michael Jeltsch
@sq
prefLabel
Michael Jeltsch
@ast
Michael Jeltsch
@ca
Michael Jeltsch
@de
Michael Jeltsch
@en
Michael Jeltsch
@es
Michael Jeltsch
@fr
Michael Jeltsch
@ga
Michael Jeltsch
@nl
Michael Jeltsch
@sl
Michael Jeltsch
@sq
P1053
I-5340-2012
P1153
6602259489
P19
P21
P214
2466155044816772520004
P27
P31
P3829
P496
0000-0003-2890-7790
P569
1969-07-28T00:00:00Z